Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512249 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5512033 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5514096 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5507449 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5506856 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5517476 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL5510321 | 1.00 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL450736 | 0.98 | NAAA (0.50) | NAAAHCAR2EPHX1TSHRRAD52 | |
| SCHEMBL444270 | 0.92 | ATM (0.54) | NAAAHCAR2EPHX1TSHRNPSR1 | |
| SCHEMBL27841060 | 0.84 | NAAA (0.53) | NAAAHCAR2EPHX1TSHRRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212325-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kukje Pharm. Ind. Co., Ltd. (KR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009066917-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-05-28 | — | — | WO | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| CN-115427081-A | Drug antibody conjugates | 法马马有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113226377-B | Antibody drug conjugates comprising an eltrinastine derivative | 法马马有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4025253-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar S.A. (ES) | 2022-07-13 | — | — | EP | disclosed |
| US-4927565-A | HYPOTENSIVE AGENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| US-4851387-A | RENIN INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| US-4847286-A | ANTIALLERGENS | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-07-11 | — | — | US | disclosed |
| EP-0272583-A2 | 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0264106-A2 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| EP-0108942-B1 | CEPHALOSPORIN DERIVATIVES, METHODS OF PRODUCTION THEREOF AND PROPHYLACTIC AND THERAPEUTIC AGENTS FOR BACTERIAL INFECTION | KYOTO PHARMA IND (JP) | 1988-03-02 | — | — | EP | disclosed |
| EP-0233946-A1 | CHROMOGLYCIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICINAL COMPOSITION | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-4605651-A | BACTERICIDES | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0108942-A2 | Cephalosporin derivatives, methods of production thereof and prophylactic and therapeutic agents for bacterial infection | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | NAAA 507/4885HCAR2 1623/4885EPHX1 1851/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | NAAA 663/4885HCAR2 3093/4885EPHX1 824/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | NAAA 1828/4885HCAR2 3414/4885EPHX1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.